Advances in The Treatment of Intrahepatic Cholangiocarcinoma-ICLCA
Oncology-Intrahepatic Cholangiocarcinoma
DOI:
https://doi.org/10.22376/ijtos.2023.1.4.13-22Keywords:
Intrahepatic cholangiocarcinoma, cholangiocarcinoma, Extrahepatic cholangiocarcinoma, Vascular Epidermal Growth Factor, IDH inhibitors, Liver CancerAbstract
Intrahepatic cholangiocarcinoma (iCLCA) is a fatal hepatobiliary tumor becoming more common. For a long time, it was largely ignored as an uncommon cancer and commonly misdiagnosed as carcinoma of unidentified origin; nonetheless, significant clinical and research attention has been dedicated to it lately. First-line (gemcitabine and cisplatin), second-line (FOLFOX), and adjuvant (capecitabine) systemic chemotherapy is the accepted standard of treatment. iCLCA is genetically unique from hepatocellular carcinoma, with multiple targetable genetic abnormalities reported to be far. Indeed, FGFR2, NTRK fusions, IDH1, and BRAF targetable mutations have been thoroughly studied, and clinical evidence on pharmacologically targeting these oncogenic drivers is emerging. In addition, the role of immunotherapy has been investigated and is a hot topic. There is a need for therapeutic interventions for these ailments. Our review focuses on Intrahepatic cholangiocarcinoma, cholangiocarcinoma, Extrahepaticcholangiocarcinoma, Vascular Epidermal Growth Factor, IDH inhibitors, and Liver Cancer.
References
Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK. Perihilar bile ducts. AJCC cancer staging atlas: A companion to the seventh editions of the AJCC cancer staging manual and handbook; 2012. p. 269-76.
Varma K, Singh A, Misra V. Cutaneous metastasis from cholangiocarcinoma presenting as thigh mass. J Clin Diagn Res. 2016 Sep;10(9):ED23-5. doi: 10.7860/JCDR/2016/21524.8584, PMID 27790452.
Talamantes S, Lisjak M, Gilglioni EH, Llamoza-Torres CJ, Ramos-Molina B, Gurzov EN. Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma. JHEP Rep. 2023 Jun 9:100811. doi: 10.1016/j.jhepr.2023.100811.
Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer. 2019;125(9):1489-98. doi: 10.1002/cncr.31942, PMID 30645774.
Chapman MH, Webster GJM, Bannoo S, Johnson GJ, Wittmann J, Pereira SP. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year singlecentre experience. Eur J Gastroenterol Hepatol. 2012;24(9):1051-8. doi: 10.1097/MEG.0b013e3283554bbf, PMID 22653260.
Lendvai G, Szekerczés T, Illyés I, et al. Cholangiocarcinoma: classification, histopathology.
Aiyadurai S, Garg T, Sayeed T, Shahbaz Z, Adewole IO, Nguty Nkeng EN et al. A case of prostatic metastasis from intrahepatic cholangiocarcinoma: an extremely rare event. Cureus. 2023 Feb 17;15(2):e35100. doi: 10.7759/cureus.35100, PMID 36938164.
Ilkovska B, Trifunova BK. Human epididymis PROTEIN 4 values in different age groups of females in Bitola, North Macedonia measured by abbot alinity CI analyzer in 2022 year.
Fernandes ED, Almeida TR, Correa RR, Braga EP, Girão CL, Pimentel LS et al. Urgent liver retransplantation due to transmission of intrahepatic cholangiocarcinoma by donor: the first report in the literature. ABCD Arq Bras Cir Dig (S Paulo). 2023 Jul 7;36:e1740.
Shao M, Xu R, Qi W, Luo Z, Liao F, Fan S. Application of 18F-FDG PET/CT imaging in gallbladder inflammatory pseudotumor with elevated CA199: a case report and review of literature. Front Oncol. 2023 Jun 5;13:1136876. doi: 10.3389/fonc.2023.1136876, PMID 37342187.
Saeed U, Uppal MR, Uppal MS, Uppal R, Khan AA, Hassan A et al. Hepatitis C virus associated ALT, AST, GGT, Bili T, HB, HBA1C, CREAT, PT, aPPT, AFP, CEA, CA 125, CA 19-9, iPTH biomarkers, computed tomography and HCV burden of disease during pre COVID-19 era (2018-2019) and post COVID-19 era (2020-2022) in Pakistan. Braz J Biol. 2023 Jun 19;84:e271451.
Abou-Ghaida J, Ali AA, Anasseri S, Walker L, Barber T. Adenocarcinoma of an unknown primary site [presentation]. Diagnosis, and management. Cureus. Vol. 15(6); 2023 Jun 28.
Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Soldà C et al. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience. Ther Adv Med Oncol. 2023 Jul;15:17588359231171574. doi: 10.1177/17588359231171574, PMID 37457302.
Do RK, Boll DT, Do RK, Boll DT. Diseases of the gallbladder and the biliary tree. InDiseases Abdomen Pelvis. 2023-2026: Diagnostic Imaging;2023(Mar 17):(121-30).
Patil S. The Accuracy of transabdominal ultrasound in obstructive jaundice as compared to magnetic resonance cholangiopancreatography.
Kim KH, Yi HS, Lee H, Bae GE, Yeo MK. Targeting the sequences of circulating tumor DNA of cholangiocarcinomas and its applications and limitations in clinical practice. Int J Mol Sci. 2023 Apr 19;24(8):7512. doi: 10.3390/ijms24087512, PMID 37108676.
Ruff SM, Pawlik TM. Surgical management of intrahepatic cholangiocarcinoma.
Olthof PB, Franssen S, van Keulen AM, van der Geest LG, Hoogwater FJH, Coenraad M et al. Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma. HPB. 2023. doi: 10.1016/j.hpb.2023.06.019.
Raoof M, Dumitra S, Ituarte PH, Melstrom L, Warner S, Fong Y et al. Intrahepatic cholangiocarcinoma: ambitious operations and outcomes. JCO. 2016;34(4_suppl):345-. doi: 10.1200/jco.2016.34.4_suppl.345.
Fighera A, Cardano G, Mazzaro A, Zamboni GA, Ruzzenente A. Mansueto G. CT enhancement pattern of intrahepatic cholangiocarcinoma predicts the presence of metastatic lymphnodes at resection. European Congress of Radiology-ECR 2019.
Spiers HV, Jegatheeswaran S, Stathakis P, Sheen A, Jamdar S, Siriwardena A. Staging laparoscopy is unnecessary in the presurgical work-up of patients with peri-hilar cholangiocarcinoma (PH-CCA). HPB. 2021 Jan 1;23:S334-5.
Reames BN. EjazA. J Surg Oncol. 2017;116:133-9.
Tripepi M, Conci S, Campagnaro T, De Bellis M, Poletto E, Marchitelli I et al. Laparoscopic hepatic resection for intrahepatic cholangiocarcinoma: a narrative review of the current literature. Laparosc Surg;6:36-. doi: 10.21037/ls-22-17.
Piccolo G, Barabino M, Lecchi F, Santambrogio R, Nava C, Opocher E et al. Laparoscopic indocyanine green fluorescence imaging for intrahepatic cholangiocarcinoma. Am Surg. 2022 May 23:00031348221103659:31348221103659. doi: 10.1177/00031348221103659, PMID 35605160.
Borad MJ. Updates in the management of hepatobiliary cancers. J Natl Compr Canc Netw. 2023 May;21:(5.5):1-3.
Chrystle M, Sanyo D. Prolonged survival with first-line chemotherapy in advanced extrahepatic cholangiocarcinoma. BMJ Case Rep. 2023 Mar 1;16(3):e249681. doi: 10.1136/bcr-2022-249681, PMID 36863754.
Moffat GT, Hu ZI, Danner De Armas A, Ross JS, Javle MM, Knox JJ. Characterizing KRAS allele variants within biliary tract cancers. JCO. 2023;41(16_suppl):4088-. doi: 10.1200/JCO.2023.41.16_suppl.4088.
Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in.
Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, openlabel.
Gopal P, Robert ME, Zhang X. Cholangiocarcinoma: pathologic and molecular classification in the era of precision medicine. Arch Pathol Lab Med. 2023 Jun 19. doi: 10.5858/arpa.2022-0537-RA, PMID 37327187.
Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in.
Cigliano A, Strain AJ, Cadamuro M. Signaling and molecular networks related to development and inflammation involved in CCA initiation and progression. Hepatoma Res;9(14). doi: 10.20517/2394-5079.2023.09.
Brown ZJ, Ruff SM, Pawlik TM. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. Expert Rev Anticancer Ther. 2023 Mar 4;23(3):257-64. doi: 10.1080/14737140.2023.2176846, PMID 36744395.
Feriz AM, Khosrojerdi A, Lotfollahi M, Shamsaki N, GhasemiGol M, HosseiniGol E et al. Single-cell RNA sequencing uncovers heterogeneous transcriptional signatures in tumor-infiltrated dendritic cells in prostate cancer. Heliyon. 2023 May 1;9(5):e15694. doi: 10.1016/j.heliyon.2023.e15694, PMID 37144199.
Chen K. Biomarkers and immunotherapy for colorectal cancer. Highlights Sci Eng Technol. 2023 Mar 21;36:1356-66. doi: 10.54097/hset.v36i.6252.
Comoglio P. Comprehensive evaluation of docking algorithms for therapeutic peptides ([doctoral dissertation]. Politecnico di Torino).
Nimura Y. Preoperative biliary drainage before resection for cholang¬iocarcinoma (Pro). HPB (Oxford). 2008;10(2):130-3. doi: 10.1080/13651820801992666, PMID 18773090.
Tavolari S, Brandi G. Mutational landscape of cholangiocarcinoma according to different etiologies: a review. Cells. 2023 Apr 22;12(9):1216. doi: 10.3390/cells12091216, PMID 37174616.
Pakharukova MY, Lishai EA, Zaparina O, Baginskaya NV, Hong SJ, Sripa B et al. Opisthorchis viverrini, Clonorchis sinensis and Opisthorchis felineus liver flukes affect mammalian host microbiome in a species-specific manner. PLOS Negl Trop Dis. 2023 Feb 13;17(2):e0011111. doi: 10.1371/journal.pntd.0011111, PMID 36780567.
Hembasat T, Chaiyadet S, Ittiprasert W, Smout MJ, Young ND, Loukas A et al. Peptide derived from progranulin of the carcinogenic liver fluke, Opisthorchis viverrini stimulates cell hyperproliferation and proinflammatory cytokine production. Res Sq. 2023. doi: 10.21203/rs.3.rs-2586058/v1, PMID 36993607.
Teixeira SV, Prates GS, Fonseca LAM, Casseb J. Can persistent infections with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T- lymphotropic virus (HTLV) be eradicated? AIDS Res Hum Retroviruses. 2023 Jul 6. doi: 10.1089/AID.2022.0116, PMID 37409405.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Anand Mohan Jha, Dr Vinayak B Angadi, Hadi Kuriri, Dr Manam Mani Srikanth, Dr Asmita Rohan Sakore
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
